The AHA publishes dozens of videos for cardiovascular professionals each year on its Science News YouTube channel.
Below you’ll find the most-watched videos published during 2020. Be sure to subscribe to the Science News channel to get the latest videos as soon as they are posted.
1. COVID-19 and the Heart
July 27, 2020
AHA volunteer Mina Chung, MD, interviews Eduardo Marban, MD, PhD, about his abstract "COVID-19 and the Heart" published in Circulation Research and presented to colleagues during the Basic Cardiovascular Sciences 2020 conference in July. See more COVID-19 science from the AHA Journals.
2. GALACTIC-HF Results
November 13, 2020
Principal investigator John Teerlink, MD, FAHA summarized results of the GALACTIC-HF trial during Scientific Sessions 2020. The trial found improving cardiac function with omecamtiv mecarbil significantly reduced the risk of a first heart failure event or cardiac death in patients with heart failure with reduced ejection fraction (HFrEF). See more trials from Scientific Sessions 2020.
3. The American Heart Association response to the COVID-19 crisis
November 27, 2020
Don Lloyd-Jones, MD, ScM and Manesh Patel, MD, chair and vice-chair of the Scientific Sessions 2020 Program Committee, discussed the ways in which the American Heart Association has responded to the COVID-19 pandemic. This video was filmed during Scientific Sessions 2020. (See more coverage from the conference.)
4. Scientific Sessions 2020 Daily Recap, Day One
November 14, 2020
AHA President Mitch Elkind, MD; Don Lloyd-Jones, MD, ScM; Biykem Bozkurt, MD, PhD, FAHA; and Manesh Patel, MD provided a recap of the first day of late-breaking science presented virtually at Scientific Sessions 2020. Topics included GALACTIC-HF, VITAL-Rhythm and the two arms of the TIPS-3 trial.
5. EMPEROR-Reduced trial results: Milton Packer, MD
August 29, 2020
Milton Packer, MD, principal investigator, summarized the results of EMPEROR-Reduced, which he presented virtually during ESC Congress 2020. The trial suggests the safety and efficacy of empagliflozin in addition to guideline-directed medical therapy as a treatment for patients with heart failure with reduced ejection fraction (HFrEF).